← Back to all trials
Active Not Recruiting
NCT07161687
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.
Conditions: Hemophilia A or B
Sex: All
Ages: 12 Years – N/A
Healthy volunteers: No
Enrollment: 50
Sponsor: Pfizer
Location: Pfizer Tokyo
Summary
A study to evaluate the safety of Hympavzi under the actual use in patients with congenital hemophilia who do not have inhibitors.
Eligibility Criteria
Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
* Patients who have received at least one dose of this drug after the launch of this drug
Source: ClinicalTrials.gov (NCT07161687). StuddyBuddy aggregates publicly available trial information.
